Cancer
Conditions
Brief summary
The goal of this clinical trial is to evaluate whether cosmeceutical topical moisturizers can help with skin dryness in participants with cancer experiencing a dermatological adverse event from cancer therapies. The main question it aims to answer is: Does cosmeceutical topical moisturizers help with skin dryness? Participants will: * Visit the clinic for a baseline visit to complete skin evaluation and tests. * Apply cosmeceutical topical moisturizers daily from baseline up until the follow-up visit. * Visit the clinic for a follow-up visit (approximately 2-4 weeks from baseline) for a repeat skin evaluation and tests.
Interventions
OTHERLa Roche Posay Lipikar Wash Atopy-Prone Plus (AP+) Moisturizing Face and Body Wash
Moisturizer wash applied once in the morning and once in the evening.
OTHERLa Roche Posay Lipikar AP+ Triple Repair Moisturizing Cream
Moisturizer applied once in the morning and once in the evening.
OTHERLa Roche Posay Cicaplast balm Panthenol/Vitamin B5 (B5+)
Balm applied once in the morning and once in the evening.
Sponsors
Stanford University
L'Oreal
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult patient (18 years or older). * Patients diagnosed with cancer. * Patient receiving cancer treatment or therapy (receiving chemotherapy, targeted treatment, hormonal therapy, and/or immune checkpoint inhibitors). * Patient experiencing a dermatological adverse event from a cancer treatment or therapy.
Exclusion criteria
* Patient is unable to understand scope of the study. * Patient is unable to provide written informed consent. * Patient is healthy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Patient-Reported Skin Dryness Severity | From baseline visit to follow-up visit (approximately 2-4 weeks). | Change in patient-reported skin dryness severity from baseline to follow-up visit (2-4 weeks) as measured by validated dryness severity scale (0-10 numerical rating scale where 0 = no dryness and 10 = severe dryness). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to improvement in dryness symptoms | From baseline visit to follow-up visit (2-4 weeks). | The time from baseline to the first documented improvement in dryness symptoms, defined as either a ≥2-point reduction in dryness severity score from baseline or patient-reported meaningful improvement in dryness symptoms, whichever occurs first. Lower values indicate a faster improvement in symptoms. |
| Change in Stratum Corneum Hydration | From baseline visit to follow-up visit (2-4 weeks). | Change in skin hydration from baseline to follow-up, measured using corneometry and reported in corneometry units (CU). Higher corneometry values indicate greater stratum corneum hydration. Positive changes from baseline reflect improved skin hydration, whereas negative changes indicate reduced hydration. |
| Change in Transepidermal Water Loss (TEWL) | From baseline visit to follow-up visit (2-4 weeks). | Change in skin barrier function from baseline to follow-up, measured by transepidermal water loss (TEWL) and reported in g/h/m². TEWL quantifies the amount of water that passively evaporates through the skin. Lower TEWL values indicate improved skin barrier integrity and reduced water loss, while higher values indicate increased barrier disruption. Negative changes from baseline reflect improvement, whereas positive changes indicate worsening skin barrier function. |
Countries
United States
Contacts
CONTACTClinical Research Coordinator
PRINCIPAL_INVESTIGATORLisa Zaba, MD, PhD
Stanford University
Outcome results
None listed